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ABSTRACT:  Gastric cancer is one of the most common malignancies. DNA methylation is implicated in
DNA mismatch repair genes deficiency. In the present study, we evaluated the methylation status of MLH1,
MSH2, MSH6 and PMS2 in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric
mucosal of gastric cancer patients from Northern Brazil. We found that none of the nonneoplastic samples
showed methylation of any gene promoter and 50% of gastric cancer samples showed at least one methylated
gene promoter. Methylation frequencies of MLH1, MSH2, MSH6 and PMS2 promoter were 21.74%, 17.39%,
0% and 28.26% respectively in gastric cancer samples. MLH1 and PMS2 methylation were associated with
neoplastic samples compared to nonneoplastic ones. PMS2 methylation was associated with diffuse- and
intestinal-type cancer compared with normal controls. Intestinal-type cancer showed significant association
with MLH1 methylation. Diffuse-type cancer was significantly associated with MSH2 methylation. Our find-
ings show differential gene methylation in tumoral tissue, which allows us to conclude that methylation is
associated with gastric carcinogenesis. Methylation of mismatch repair genes was associated with gastric
carcinogenesis and may be a helpful tool for diagnosis, prognosis and therapies. However, MSH6 does not
seem to be regulated by methylation in our samples.
Introduction
Gastric cancer is the fourth most common malig-
nancy and the second most common cause of cancer
death worldwide (Parkin et al., 2002). In Northern Bra-
zil, the state of Pará has a high incidence rate of this
neoplasia and its capital, Belém, was ranked eleventh
in number of gastric cancers per inhabitant among all
cities worldwide with cancer records (INCA, 2005).
DNA methylation is the most studied epigenetic
alteration, occurring through the addition of a methyl
radical to the cytosine base adjacent to guanine (Bird,
2002). In cancer, DNA methylation of the promoter re-
gion of a normal tumor-suppressor gene leads to the
aberrant silencing of its functions.
Genetic pathways involved in gastric cancer devel-
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opment are not clearly understood, although several
genetic and epigenetic alterations have been implicated
in DNA mismatch repair (MMR) genes deficiency, re-
sulting in microsatellite instability (MSI) phenotype. The
human MMR system repairs DNA replication errors or
physicochemical damage. Microsatellite regions are
susceptible to mutation due to slippage of DNA poly-
merase during DNA replication. Failure to excise these
errors may lead to frameshift mutations in many target
genes (Bacani et al., 2005). MLH1, MSH2, MSH6 and
PMS2 are major MMR genes implicated in genetic sta-
bility (Gologan and Sepulveda, 2005).
The MSI phenotype that occurs in tumors has been
demonstrated to be due to deficiency of one of the main
DNA MMR proteins (MLH1 and MSH2) (Boland,
2000). Hypermethylation of MLH1 promoter CpG is-
land was found responsible for the development of most
gastric cancers exhibiting MSI (Fleisher et al., 1999).
MLH1 may form heterodimers with PMS2 acting as
molecular matchmakers, recruiting other proteins of
MMR complex (Kunkel and Erie, 2005). However,
PMS2 methylation status has never been studied in gas-
tric carcinogenesis. MSH2 has also been implicated in
gastric carcinogenesis (Kim et al., 2001; Kitajima et
al., 2003). MSH2 may form heterodimers with MSH6
repairing single base-base and 1–2 base insertion-dele-
tion mismatches (Kunkel and Erie, 2005). Few studies
assessed MSH2 methylation frequency (Wu et al., 2000;
Fang et al., 2004), but MSH6 methylation status has
never been studied in gastric carcinogenesis.
The knowledge of the methylation status of DNA
MMR can help understanding a major gastric carcino-
genesis pathway. Tumor-specific epigenetic alterations
can be used as molecular markers of malignancy, and
thus provide more specific therapy. In the present study,
we evaluated the methylation status of MLH1, MSH2,
MSH6 and PMS2 promoters, as well as their potential
association with clinical and pathological characteris-
tics, such as gender, age, histopathology, tumor exten-
sion and presence of lymph nodes or distant metastasis.
Materials and Methods
Samples
The study included 66 gastric tissue samples. Of
them, 20 were nonneoplastic gastric mucosa of gastric
cancer patients (at a distance form the primary tumor)
and 46 sporadic gastric cancer samples. Gastric
samples were surgically obtained at João de Barros
Barreto University Hospital (HUJBB) in the state of
Pará. Patients had never been submitted to either che-
motherapy or radiotherapy prior to surgery, nor had
any other diagnosed cancer. All patients signed an in-
formed consent approved by Research Ethics Commit-
tees of HUJBB and Ribeirão Preto Medical School
Clinics Hospital. All 46 gastric cancer samples were
classified according to Laurén (1965): 20 were dif-
fuse-type and 26 were intestinal-type. Tumors were
TABLE 1.
Primer sequences (5’-3’) for MSP
M: methylated sequence; U: unmethylated sequences.
Gene Sense Antisense Product size
MLH1 M-TTACGGGTAAGTCGTTTTGAC M-CTATACCTAATCTATCGCCGC 154 pb
U-TATGGGTAAGTTGTTTTGATGT U-CCTATACCTAATCTATCACCACC 154 pb
MSH2 M-AGTTAAAGTTATTAGCGTGCG M-CTAATTAAAAAAAATACGCGAC 199 pb
U- AGTTAAAGTTATTAGTGTGTGTGG U-TCCTAATTAAAAAAAATACACAAC 202 pb
MSH6 M-GGTCGTAATTAATTTCGGGTC M-CCAATAACCAATCAACAAACG 252 pb
U-GTTGTAATTAATTTTGGGTTGG U-CCAATAACCAATCAACAAACAC 251 pb
PMS2 M-GGTCGGTCGGTATAGATGTC M-CAAATAAAACCCTATCACGAA 252 pb
U-TTGGTTGGTATAGATGTTGG U-CCAAATAAAACCCTATCACAA 251 pb
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FIGURE 1. a) Examples of gel electrophoresis using MLH1, MSH2, MSH6 and PMS2 MSP primers. L: size
marker; M: methylated; U: unmethylated. b) Methylated and unmethylated samples of MLH1 used as posi-
tive control for DNA bisulfite treatment, when compared to untreated sequence.
staged using TNM staging criteria (Sobin and
Wittekind, 2002).
Methylation-specific PCR (MSP)
Genomic DNA was extracted from gastric samples
using phenol-chloroform extraction. Genomic DNA (2
μg) was modified by bisulfite treatment, converting
unmethylated cytosines to uracils and leaving methy-
lated cytosines unchanged. MSP was performed on
treated DNA as previously described (Herman et al.,
1996). Specific primers for MSP (Table 1), located
within CpG islands in gene promoter, were designed
using the Methprimer software (Li and Dahiya, 2002).
PCR was carried out in a volume of 50 μl with 200
μmol/L of dNTPs, 200 μmol/L of MgCl2, 50 ng of DNA,
200 pmol/L of primers and 1 unit of AmpliTaq GOLD
(Applied Biosystems, Foster City, CA, USA). After ini-
tial denaturing for 2 min at 94ºC, 35 cycles at 94ºC for
40 s, 50–60ºC for 1 min and 72ºC for 40 s were carried
out, followed by a final extension at 72ºC for 5 min. PCR
products were separated and visualized using 8% poly-
acrylamide gel stained with 10% silver nitrate (Fig. 1).
Water was used as negative control. MSP results were
scored when there was a clearly visible band on electro-
phoresis gel with methylated and unmethylated primers
(Herman et al., 1996).
Sequencing of a methylated and then an un-
methylated PCR product of MLH1 was used as a control
for DNA bisulfite treatment. For sequencing analysis, ABI
PRISM Big Dye Terminator Cycle Sequencing Kit (Perk-
ing Elmer, Alameda, CA, USA) was used (Fig. 1).
Statistical analysis
Statistical analyses were performed using Fisher’s
exact test to assess associations between methylation
status and frequency, and clinical and pathological char-
acteristics, such as gender, age, histopathology, tumor
extension and presence of lymph nodes or distant me-
tastasis. A 5% significance level was set.
Results
Of 66 patients studied, 47 were males and 19 were
females, and mean age was 59 ±9.8775 years (range
27–76). According to Laurén’s classification, 20 were
diffuse-type and 26 were intestinal-type. All gastric can-
cer samples were in advanced stage.
Sequencing of a methylated and an unmethylated
PCR product of MLH1, used as controls for DNA bisulfite
treatment, showed methylated and unmethylated (con-
verted) cytosines, respectively, at CpG-sites when com-
pared to non-treated sequence of DNA. At non-CpG sites,
all cytosines were converted to thymine (Fig. 1). This
excluded the possibility that successful amplification with
methylated primers could be attributable to incomplete
bisulfite conversion.
Table 2 shows clinical and pathological character-
istics and methylation status of MLH1, MSH2, MSH6
and PMS2 promoters of the samples studied. None of
the nonneoplastic samples showed methylation of any
gene promoter. Of all gastric cancer samples, 50%
showed at least one methylated gene promoter. Methy-
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lation frequencies of MLH1, MSH2, MSH6 and PMS2
promoters were 21.74%, 17.39%, 0% and 28.26% re-
spectively in gastric cancer samples (Table 3).
MLH1 and PMS2 methylation were associated with
gastric cancer samples compared to nonneoplastic
samples (p=0.0256 and p=0.0065, respectively). A ten-
dency for MSH2 promoter methylation in gastric can-
cer compared to normal controls was seen (p=0.0531)
(Table 3).
Higher PMS2 methylation frequency was associ-
ated with diffuse- (p=0.0471) and intestinal-type gas-
tric cancer (p=0.0065) compared with normal controls.
Intestinal-type gastric cancer showed a significant as-
sociation with higher MLH1 methylation frequency
(p=0.0287). In diffuse-type gastric cancer samples, it
was detected an association between this cancer type
and higher MSH2 methylation frequency (p=0.0471)
(Table 3).
TABLE 2.
Clinical and pathological characteristics and methylation status of MLH1,
MSH2, MSH6 and PMS2 promoters of the studied samples.
White boxes: samples that showed unmethylated sequences; black boxes: samples that showed methylated sequences.
T: size or direct extent of the primary tumor; N: degree of spread to regional lymph nodes; M: presence of metastasis.
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In our study, we found that none of the samples
with MLH1, MSH2 or PMS2 methylation showed
unmethylation sequences using MS-PCR assay. MSP is
a sensitive method able to detect at least 0.1% of me-
thylated or unmethylated genes. Our results suggest that
methylation of these genes is a common event in a sub-
group of gastric cancers and may be related to early
carcinogenesis.
We evaluated a CpG island of MLH1 promoter pre-
viously described as associated with its gene expres-
sion and MSI status (Herman et al., 1998). In the present
study, MLH1 methylation was found in 21.74% of gas-
tric cancer samples, which was not significantly differ-
ent from previously described frequencies (13–41%)
(Leung et al., 1999; Toyota et al., 1999; Fang et al.,
2003; An et al., 2005; Truninger et al., 2005).
Hypermethylation of the MLH1 promoter CpG island
was found responsible for the development of the ma-
jority of gastric neoplasias exhibiting MSI (Fleisher et
al., 1999) and was previously associated with high-de-
gree MSI (MSI-H) in gastric cancer (Leung et al., 1999;
Toyota et al., 1999; Wu et al., 2000; Fang et al., 2003;
An et al., 2005).
We also found an association between MLH1 me-
thylation and gastric carcinogenesis, especially in in-
testinal-type samples. Wu et al. (2000) described that
MSI-H is significantly more common in antral loca-
tion, intestinal subtype and H. pylori seropositivity
samples. Thus, our data corroborate Wu et al.’s (2000)
findings concerning the association between MLH1
methylation and intestinal-type gastric cancer. Kitajima
TABLE  3.
Methylation number and frequency in gastric tissue samples, n (%), and
p-values for comparison of gastric cancer with nonneoplastic samples.
M: methylated; U: unmethylated; ap<0.05.
The statistical analysis showed an association be-
tween methylation of MLH1, MSH2 or PMS2 promoter
in gastric cancer (p<0.0001), and both diffuse-
(p=0.0004) and intestinal-type (p=0.0001) compared to
nonneoplastic samples.
We analyzed whether DNA methylation was asso-
ciated with clinical and pathological characteristics, and
detected a tendency for PMS2 methylation in intesti-
nal-type gastric cancer with larger tumor extension (T3
and T4) (p=0.0622).
Discussion
There are at least two distinct genetic instabilities
in gastric tumorigenesis. One is microsatellite instabil-
ity (or MSI pathway) and the other is chromosomal in-
stability (or suppressor pathway), including tumors with
low-frequency MSI (MSI-L) as well as microsatellite
stable (MSS) with accumulation of loss of tumor sup-
pressor genes, such as TP53, RB, APC, MCC and DCC.
The MSI pathway consisting of a gastric cancer subset
with high-frequency MSI (MSI-H) and the defective
repair of mismatched bases induces increased mutation
rate at the nucleotide level, and the consequent wide-
spread MSI (Martins et al., 1999; Wu et al., 2000; Fang
et al., 2001). In the present study, 50% of gastric cancer
samples showed at least one methylated gene promoter
and methylation of MLH1, MSH2 or PMS2 promoter
was significantly associated with this cancer, suggest-
ing that this tumor develops by a MSI pathway.
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et al. (2003) also described that loss of MHL1 expres-
sion is associated with differentiated gastric cancer
samples, which is roughly consistent with intestinal-type
cancer according to Laurén’s classification.
To the best of our knowledge, only one study evalu-
ated PMS2 methylation status, but no correlation was
found between the lack of PMS2 expression and this
gene methylation (0% of methylation) in colorectal can-
cer (Truninger et al., 2005). The present study it is the
first to evaluate PMS2 methylation status in gastric can-
cer. We found PMS2 methylation in 28.26% of gastric
cancer samples studied and it was associated with both
intestinal- and diffuse-type gastric cancer compared to
normal controls. It was also detected a tendency for
PMS2 methylation in intestinal-type gastric cancer with
larger tumor extension. However, further studies on
PMS2 methylation are needed to better understand this
finding in gastric carcinogenesis.
MSH2 methylation status was only evaluated in two
other studies on gastric carcinogenesis (Wu et al., 2000;
Fang et al., 2004). All studies, including the present
study, evaluated the same CpG island that was previ-
ously associated with MSH2 expression (Wang et al.,
2003). Wu et al. (2000) have not found MSH2 methyla-
tion in 42 samples studied. Fang et al. (2004) performed
bisulfite modification and sequencing of MSH2 in can-
cerous, paracancerous and non-cancerous tissues from
ten patients and found that methylation occurred only
at the -166 CpG site. In our samples, we found MSH2
methylation in 17.39% of samples studied and a ten-
dency for MSH2 promoter in gastric cancer compared
to normal controls. Thus, MSH2 methylation frequency
in our study population was higher than that found in
Asian populations.
We also found an association between MSH2 me-
thylation and diffuse-type gastric cancer samples.
Kitajima et al. (2003) previously described an associa-
tion between loss of MSH2 expression and undifferen-
tiated gastric cancer type, largely corresponding to dif-
fuse-type in Laurén’s classification, in a Japanese
population.
MSH6 was previously described as a potential tran-
scriptionally silenced gene by cytosine methylation
(Bearzatto et al., 2000; Gazzoli and Kolodner, 2003).
The 5’-flanking region of MSH6 gene was found to com-
prise seven functional Sp1 transcription factor binding
sites, each binding to Sp1 and Sp3 and contributing to
promoter activity. The Sp1-4, Sp1-5, Sp1-6, and Sp1-7
sites have a paramount role in this activity and allow
DNA methylation to inhibit Sp1 binding (Gazzoli and
Kolodner, 2003).
The methylation status of MSH6 has not been re-
ported in any primary tumor. In the present study, we
evaluated the methylation status of MSH6 region which
comprises the most important Sp1 sites. However, we
did not detect MSH6 methylation in any gastric speci-
men, suggesting that MSH6 methylation is not a major
event for gastric carcinogenesis in the samples studied.
The integrity of genetic information depends on the
fidelity of DNA replication and the efficiency of sev-
eral different DNA repair processes. The identification
of epigenetic modifications in MMR genes and the de-
termination of the frequency of alterations may be a
useful tool for developing more specific cancer thera-
pies. This is the first study evaluating the methylation
status of MLH1, MSH2, MSH6 and PMS2 promoters
and their hypermethylation frequencies in gastric tissue
samples in a population from Northern Brazil. The me-
thylation status of PMS2 and MSH6 promoter had never
been investigated before in gastric samples. Our find-
ings show that methylation of MLH1, MSH2 and PMS2
MMR genes is associated with gastric carcinogenesis.
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